Midcareer Mentoring Award for Patient-Oriented Research in Chlamydia trachomatis Infection

沙眼衣原体感染以患者为导向的研究职业生涯中期指导奖

• 批准号: 10591326
• 负责人: WILLIAM M GEISLER
• 金额: $ 15.13万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-06-01 至 2027-10-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10591326
• 关键词: Address; Adolescent; Affect; African American population; Age; Alabama; Antibodies; Antigens; Area; Atopobium vaginae; Award; Behavioral; Biological Markers; Blood; Chlamydia; Chlamydia trachomatis; Clinic; Clinical Investigator; DNA; Development; Disparity; Doctor of Medicine; Education; Educational process of instructing; Enrollment; Entrepreneurship; Enzyme-Linked Immunosorbent Assay; Female; Frequencies; Funding; Genital; Genitalia; Goals; Gynecology; HIV risk; HLA-DQ Antigens; HLA-DQB1; Health; Human Papilloma Virus Vaccine; Immunity; Immunogenetics; Infection; Infection Control; Infection prevention; Interferon Type II; International; Interview; Knowledge; Leadership; Learning; Linkage Disequilibrium; Master of Public Health; Mediating; Mentors; Mentorship; MicroRNAs; Mid-Career Clinical Scientist Award (K24); Midcareer Investigator Award in Patient-Oriented Research; Mucous Membrane; Patients; Physicians; Population; Positioning Attribute; Prevention; Public Health; Publications; Reporting; Research; Research Activity; Research Personnel; Research Project Grants; Respondent; Risk; Risk Marker; Scientist; Secure; Serum; Source; Specimen; Students; Surveys; Swab; T cell response; T-Lymphocyte; TNFSF15 gene; Testing; Time; Training; Translating; United States National Institutes of Health; Universities; Vaccines; Variant; Visit; Woman; antigen test; bench to bedside; career; career development; chlamydia vaccine; clinical practice; commercialization; coronavirus disease; design; early experience; experience; immunogenic; improved; infection rate; infection risk; insight; interest; male; patient oriented research; perinatal morbidity; predictive marker; programs; psychosocial; recruit; reproductive; reproductive morbidity; research study; response; sample collection; screening; skill acquisition; skills; success; vaccine acceptance; vaccine access; vaccine candidate; vaccine development; vaccine trial; young woman

This application is for a renewal of my K24 Midcareer Investigator Award in Patient-Oriented Research (POR) on Chlamydia trachomatis (CT) Infections. I, Dr. William Geisler, am a federally-funded physician scientist at the University of Alabama at Birmingham (UAB) with expertise in CT infections and significant mentoring experience. During the initial K24 period, I obtained new funding (R01 renewal, a new R01, a new R21, etc.), expanded my POR program in new directions, had 35 publications, became UAB Assistant Dean for Physician Scientist Development, and mentored 16 early stage investigators who had many successes (awards included a K08, KL2, TL1, an F30, an F31-D, etc.). The protected time afforded by this K24 renewal would enable me to: 1) broaden my mentoring knowledge and develop new research skills, 2) continue providing POR mentoring to early stage investigators, and 3) expand my research program in new directions. Despite current CT prevention and control efforts, CT infection rates continue to rise and CT remains the most prevalent bacterial STI worldwide, one with significant disparities in women and African Americans and associated with reproductive morbidity. A CT vaccine is urgently needed. However, a better understanding of immunogenetic determinants that impact CT infection risk and which CT antigens are most immunogenic and induce protective immunity to CT is needed to advance vaccine development; My Current POR is focused on this need (2R01AI093692 and 1R01AI148359). CT vaccine availability does not ensure it will be utilized. Lessons learned from HPV vaccine implementation have taught us that psychosocial and behavioral factors influence STI vaccine acceptability and studies on factors impacting CT vaccine acceptability are needed. In this K24 renewal, I plan to broaden my mentoring knowledge through didactic and interactive experiences, develop new research skills in entrepreneurship and research commercialization through didactic and experiential training under mentorship, and continue mentoring early stage investigators in POR. Mentees will be provided with educational and research experiences tailored to their career stage and interests. Mentoring will be on my Current CT immunogenetics POR (noted above and discussed in detail in this application) and on two new POR studies suported by this K24 renewal award that will expand my CT POR program. New Study 1 aims to determine if HLA-DQB1*06 and CT-specific CD4+ IFN-g can be useful biomarkers for predicting incident CT infection; I previously found that DQB1*06 was a risk marker and CD4+ IFN-g a protective marker for CT reinfection. Findings can be used to guide CT testing frequency in women based on incident CT infection risk determined by the biomarkers. New Study 2 seeks to identify enabling and limiting factors that affect acceptability of a CT vaccine through surveys and qualitative interviews to aid in designing strategies to increase CT vaccine uptake. The long-term goal of my POR is to improve prevention and control of CT infection. Thus, knowledge from Current POR and new studies addresses this goal.

这份申请书是为了续订我的K24年度以病人为中心的研究的职业中期研究人员奖 (POR)沙眼衣原体(CT)感染。我，威廉·盖斯勒医生，是联邦政府资助的医生 阿拉巴马大学伯明翰分校(UAB)的科学家，拥有CT感染和显著 指导经验。在最初的K24期间，我获得了新的资金(R01续订、新的R01、新的 R21等)，将我的POR计划扩展到新的方向，有35本出版物，成为UAB助理院长 医生科学家发展，并指导了16名早期研究人员，他们取得了许多成功 (奖项包括K08、KL2、TL1、F30、F31-D等)。此次K24续订所提供的保护时间 使我能够：1)拓宽我的指导知识，发展新的研究技能；2)继续 为早期研究人员提供POR指导，以及3)在新的方向上扩展我的研究计划。 尽管目前做出了预防和控制CT的努力，但CT感染率继续上升，CT仍然是最多的 细菌性传播感染在世界范围内流行，在女性和非裔美国人中差异显著 与生殖疾病有关。迫切需要一种CT疫苗。然而，更好地理解 影响CT感染风险的免疫遗传决定因素以及哪些CT抗原最具免疫原性和 诱导对CT的保护性免疫是推进疫苗开发所必需的；我目前的POR重点是 此需要(2R01AI093692和1R01AI148359)。CT疫苗的可获得性并不能确保它会被利用。 从实施HPV疫苗中吸取的教训告诉我们，心理社会和行为因素 影响STI疫苗可接受性的研究和影响CT疫苗可接受性因素的研究。 在这次K24更新中，我计划通过授课和互动来拓宽我的指导知识 通过教学，在创业和研究商业化方面积累经验，发展新的研究技能 并在导师的指导下进行体验式培训，并继续指导POR的早期调查人员。受训者 将为他们提供适合其职业阶段和兴趣的教育和研究经验。 我将指导我目前的CT免疫遗传学POR(如上所述，并在本文中详细讨论 申请)和此K24续订奖支持的两项新POR研究，将扩展我的CT POR 程序。新的研究1旨在确定人类白细胞抗原-DQB1*06和CT特异性的CD4+干扰素-g是否有用 预测CT感染事件的生物标记物；我以前发现DQB1*06是一个危险标记物，而CD4+ 干扰素-g是CT再感染的保护性标志物。这些发现可以用来指导女性的CT检查频率 根据生物标志物确定的事件CT感染风险。新的研究2寻求确定赋权和 通过调查和定性访谈影响CT疫苗可接受性的限制因素以帮助 设计增加CT疫苗接种率的策略。我的POR的长期目标是改善预防 控制沙眼衣原体感染。因此，来自当前POR和新研究的知识解决了这一目标。